Company Insights

JUNS supplier relationships

Explore interactive graphBrowse insights index
JUNS supplier relationship map

Jupiter Neurosciences (JUNS): supplier map and operational constraints that matter to investors

Jupiter Neurosciences develops and commercializes a resveratrol-based therapeutic and consumer product platform (JOTROL / Nugevia). The company monetizes through a two-track model: clinical-stage drug development and licensing/consumer product sales, supported by third‑party manufacturing, strategic licensing, and capital partnerships that fund near-term trials and commercialization. For investors and supply‑chain operators, the key signal is that Jupiter operates with mixed long‑term strategic services and transactional spot purchasing, which concentrates operational risk on a small set of manufacturing and development partners while commercial expansion leans on licensing and distribution arrangements. Learn more about supplier exposures and relationship detail at https://nullexposure.com/.

Quick read: what drives value and what to watch

Jupiter’s value inflection points come from clinical progress in Parkinson’s and commercial rollout of Nugevia consumer lines. Manufacturing and formulation rights are core to execution — any disruption at contract manufacturers or license partners will affect both trial timelines and retail supply. Capital structure support from specialty financiers reduces immediate liquidity pressure but introduces repayment and covenant timing as execution risks.

For deeper supplier intelligence on JUNS, visit https://nullexposure.com/.

How Jupiter structures external relationships (operating posture)

Jupiter blends several contracting styles:

  • Licensing relationships are material to product commercialization — the company holds exclusive commercialization rights while often granting formulation and manufacturing rights to partners (explicit in filings with Aquanova and historical license language).
  • Strategic multi‑year services exist for market entry in APAC (e.g., Dominant Treasure strategic services with a 36‑month term) and technical CMC/regulatory support, indicating an explicit push into Southeast Asia as part of commercialization strategy.
  • Spot purchasing for drug supply is a real operational constraint — the company states it buys drug product on purchase orders and does not have comprehensive long‑term supply agreements for all inputs, creating supply continuity risk for trials.
  • Third‑party CROs, CMOs and consultants are critical service providers for trials, protocol design, biomarker planning and site selection; these dependencies are active and operationally critical.

Key spend signals at the company level include: annual license fees in the sub‑$100k band (Aquanova $75k), multi‑million one‑time strategic service fees ($2.3m to Dominant Treasure), and milestone/territory fees ($100k per territory to MCRI up to $300k) — these figures frame cash outflows tied to licensing and market approvals.

Relationship map — who Jupiter works with and why it matters

Catalent Pharmaceutical Services, Inc.

Catalent is contracted to manufacture clinical trial supplies for Jupiter’s Phase IIa Parkinson’s trial, making Catalent a critical manufacturing partner for upcoming clinical milestones. This relationship is documented in Jupiter’s FY2024 10‑K and reiterated in company press materials referencing Catalent as the manufacturing partner (FY2024 10‑K; GlobeNewswire, Dec 3, 2025).

Aquanova AG

Aquanova holds micellar technology patents and has granted Jupiter a worldwide license to develop, manufacture, distribute and sell JOTROL; Aquanova also retains formulation and manufacturing roles under the collaboration and receives an annual license fee (company license agreement disclosures; press release March 4, 2025). According to company filings and announcements, Aquanova is a formal licensing and formulation partner (License Agreement II language; GlobeNewswire/March 2025).

B2i Digital, Inc.

B2i Digital has been retained for capital markets positioning — Jupiter was selected as a B2i Featured Company to amplify investor outreach and corporate narrative as the Parkinson’s program and consumer launch scale (TradingView / EQS News, Feb–Mar 2026).

YA II PN, Ltd.

YA II PN, Ltd. is the counterparty to convertible promissory notes and related standby equity purchase agreements; Jupiter entered an Omnibus Amendment modifying installment payment provisions to align capital delivery with execution timelines (company press release summarized by Futunn and DelawareOnline, Mar 2026).

ANNIKA Women’s All Pro Tour (ANNIKA WAPT)

Jupiter’s Nugevia consumer brand will supply products and educational materials to ANNIKA WAPT professionals during the season, representing a distribution/brand partnership to support consumer visibility and sampling (TheGolfWire press release, Mar 2026).

Zina Biopharmaceuticals, LLC

Zina is providing trial protocol design, pharmacokinetic and biomarker planning, and assistance with site selection for the Phase IIa Parkinson’s trial, positioning Zina as an external clinical development advisor and CRO collaborator (GlobeNewswire press release Nov 5, 2025; Yahoo Finance summary).

Dominari Securities

Dominari Securities acted as the sole bookrunner for Jupiter’s IPO, indicating the firm’s role in capital markets execution at listing (Renaissance Capital IPO coverage, FY2024).

Cherry Bekaert LLC

Cherry Bekaert was ratified as Jupiter’s independent auditor for the 2025 fiscal year, a governance and financial reporting relationship (press release reported by The Globe and Mail, FY2025).

Yorkville Advisors / Yorkville

Yorkville Advisors is providing access to up to $20 million in financing to support the Phase II Parkinson’s trial and commercial expansion for Nugevia; Yorkville’s capital facility underpins near‑term liquidity and program funding (TradingView / EQS press releases, 2025).

Nasdaq

Jupiter completed its public listing on the Nasdaq under the ticker JUNS, establishing the exchange venue for equity liquidity and reporting obligations (Renaissance Capital coverage, FY2024).

RedChip Companies

RedChip hosted an investor webinar featuring Jupiter’s CEO, supporting investor education and outreach ahead of clinical and commercial milestones (GlobeNewswire press release Dec 23, 2025).

NovaSOL®

NovaSOL® Astaxanthin is included in Nugevia™ GLO consumer formulations, signaling third‑party ingredient sourcing and co‑formulation for beauty/skin offerings (MacauBusiness launch coverage, FY2025).

Money Channel NYC

Money Channel NYC organized an investor dinner where Jupiter was invited to present clinical and commercial updates, indicating investor relations channels beyond standard roadshows (ManilaTimes reporting Feb 25, 2026).

EIN Presswire

EIN Presswire acted as a distribution channel for certain Nugevia expansion announcements, representing PR distribution rather than a technical supplier (press release distribution noted in Desert Sun coverage, FY2026).

Operational implications and investment risk/reward

  • Concentration risk: A small number of manufacturing and clinical partners (Catalent, Aquanova, Zina) are operationally critical; any disruption at these partners would directly delay trial timelines and commercial supply.
  • Contract mix: Jupiter runs both long‑term strategic services (multi‑year APAC agreements) and spot purchase exposure for drug supply, creating a hybrid risk posture: long‑run market access versus short‑run supply fragility.
  • Capital partnerships: Yorkville and YA II provide essential funding flexibility, but amendments to installment timing reflect sensitivity to execution pace and impose future repayment sequencing investors must track.
  • Cost posture: The company’s disclosed payment bands (annual license fees under $100k to Aquanova, a $2.3m one‑time strategic payment, and territory milestone fees of $100k each to MCRI) define discrete cash obligations tied to approvals and commercialization.

For operational due diligence and supplier monitoring on JUNS, see detailed supplier intelligence at https://nullexposure.com/.

Conclusion — what investors should watch next

Track three near‑term indicators: Catalent’s production timelines for Phase IIa supplies, regulatory and biomarker workstreams led with Zina, and the timing and sizing of Yorkville/YA II capital installments. These factors control cash flow, trial momentum, and commercial launch cadence — the drivers of valuation re‑rating for JUNS.

If you need a tailored supplier risk briefing for JUNS or comparative exposure across peers, request a report at https://nullexposure.com/.